Advertisement

Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis

Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis††Conflicts of interest: Dr. White reports receiving research support during the past 12 months from the National Institutes of Health, Bethesda, Maryland; the Catherine and Patrick Donaghue Medical Research Foundation, West Hartford, Connecticut; the American Heart Association, Dallas, Texas; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. Dr. White presently serves as a safety consultant to Gilead Sciences, Inc., Foster City, California; Myriad Genetics, Inc., Salt Lake City, Utah; NicOx S.A., Sophia-Antipolis, France; Takeda Research and Development Group, Deerfield, Illinois; and Teva Neuroscience, Inc., Kansas City, Missouri. Dr. Schnitzer reports receiving research support from the National Institutes of Health; Pfizer Laboratories, Inc., New York, New York; Wyeth Laboratories, Madison, New Jersey; Nordic Bioscience, Herlev, Denmark; Novartis Pharmaceuticals Corporation; Genzyme Corporation, Cambridge, Massachusetts; and Pozen, Inc., Chapel Hill, North Carolina. Dr. Schnitzer presently serves as a consultant to Logical Therapeutics, Inc., Waltham, Massachusetts; NicOx, Inc., Warren, New Jersey; Merck & Company, Inc., Whitehouse Station, New Jersey; SantoSolve AS, Oslo, Norway; Solstice Neurosciences, South San Francisco, California; and Horizon Therapeutics, Northbrook, Illinois. Dr. Schnitzer is a noninvested shareholder of NicOx S.A. Mrs. Fleming is an employee of NicOx, Inc. Drs. Duquesroix and Beekman are employees of NicOx, S.A.
      Traditional nonsteroidal anti-inflammatory drugs are associated with the destabilization of blood pressure (BP) control, particularly in hypertensive patients treated with blockers of the renin-angiotensin system. To assess the potential impact of nitric oxide donation, the effects of naproxcinod with naproxen and placebo on changes in BP were compared in a randomized clinical trial of 916 patients with osteoarthritis after 13 weeks of therapy. In addition, the effects of naproxcinod versus naproxen and placebo on systolic BP in patients with hypertension treated with renin-angiotensin system blockers were evaluated. Naproxcinod 750 mg twice daily reduced systolic BP compared to naproxen 500 mg twice daily (p <0.02). The 2 doses of naproxcinod showed reductions from baseline in diastolic BP relative to naproxen (p <0.04) and similar changes compared to placebo. In 207 patients with hypertension treated with renin-angiotensin–blocking agents alone or with diuretics, the difference in mean change from baseline in systolic BP between naproxen 500 mg and naproxcinod 750 mg was 6.5 mm Hg in favor of naproxcinod (p <0.02). The proportion of patients in the overall population with systolic BP increases ≥10 mm Hg was greater with naproxen 500 mg (22%) compared to naproxcinod 750 mg (14%, p = 0.04), naproxcinod 375 mg (14%, p = 0.055), and placebo (15.6%, p = 0.155). In conclusion, naproxcinod did not induce elevations of BP seen with naproxen, and it had similar effects on BP to that of placebo in patients with osteoarthritis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schnitzer T.J.
        • Kivitz A.J.
        • Lipetz R.S.
        • Sanders N.
        • Hee A.
        Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee.
        Arthritis Rheum. 2005; 53: 827-837
        • Rees D.D.
        • Palmer R.M.
        • Moncada S.
        Role of endothelium-derived nitric oxide in the regulation of blood pressure.
        Proc Natl Acad Sci U S A. 1989; 86: 3375-3378
        • Moncada S.
        • Higgs E.A.
        The discovery of nitric oxide and its role in vascular biology.
        Br J Pharmacol. 2006; 147: S193-S201
      1. Medical Dictionary for Regulatory Activities Terminology: Version 9.1.
        Maintenance and Support Services Organization, Reston, Virginia2006
        • Whelton A.
        • White W.B.
        • Bello A.E.
        • Puma J.A.
        • Fort J.G.
        • SUCCESS-VII Investigators
        Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis.
        Am J Cardiol. 2002; 90: 959-963
        • Morgan T.O.
        • Anderson A.
        • Bertram D.
        Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril.
        Am J Hypertens. 2000; 13: 1161-1167
        • Muscara M.N.
        • McKnight W.
        • Del Soldato P.
        • Wallace J.L.
        Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat.
        Life Sci. 1998; 62: 235-240
        • Lohmander L.S.
        • McKeith D.
        • Svensson O.
        • Malmenas M.
        • Bolin L.
        • Kalla A.
        • Genti G.
        • Szechinski J.
        • Ramos-Remus C.
        • STAR Multinational Study Group
        A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
        Ann Rheum Dis. 2005; 64: 449-456
        • White W.B.
        Cardiovascular effects of the cyclooxygenase inhibitors.
        Hypertension. 2007; 49: 408-418
        • Izhar M.
        • Alausa T.
        • Folker A.
        • Hung E.
        • Bakris G.L.
        Effects of COX-inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics.
        Hypertension. 2004; 43: 574-577
        • White W.B.
        • Kent J.
        • Taylor A.
        • Verburg K.M.
        • Lefkowith J.B.
        • Whelton A.
        Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.
        Hypertension. 2002; 39: 929-934
        • Houston M.C.
        • Weir M.
        • Gray J.
        • Ginsberg D.
        • Szeto C.
        • Kaihlenen P.M.
        • Sugimoto D.
        • Runde M.
        • Lefkowitz M.
        The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.
        Arch Intern Med. 1995; 155: 1049-1054
        • Klassen D.K.
        • Jane L.H.
        • Young D.Y.
        • Peterson C.A.
        Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine.
        Am J Hypertens. 1995; 8: 146-153
        • MacDonald T.M.
        • Reginster J.Y.
        • Littlejohn T.W.
        • Richard D.
        • Lheritier K.
        • Krammer G.
        • Rebuli R.
        Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
        J Hypertens. 2008; 26: 1695-1702
        • Pope J.E.
        • Anderson J.J.
        • Felson D.T.
        A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure.
        Arch Intern Med. 1993; 153: 477-484
        • Johnson A.G.
        • Nguyen T.V.
        • Day R.O.
        Do nonsteroidal anti-inflammatory drugs affect blood pressure?.
        Ann Intern Med. 1994; 121: 289-300
        • Grover S.A.
        • Coupal L.
        • Zowall H.
        Treating osteoarthritis with cyclooxygenase-2 specific inhibitors: what are the benefits of avoiding blood pressure destabilization?.
        Hypertension. 2005; 45: 92-97
        • White W.B.
        Benefits of antihypertensive therapy in older patients with hypertension.
        Arch Intern Med. 2000; 160: 149-150
        • Julius S.
        • Kjeldsen S.E.
        • Weber M.
        • Brunner H.R.
        • Ekman S.
        • Hansson L.
        • Hua T.
        • Laragh J.
        • McInnes G.T.
        • Mitchell L.
        • Plat F.
        • Schork A.
        • Smith B.
        • Zanchetti A.
        • VALUE Trial Group
        Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
        Lancet. 2004; 363: 2022-2031
        • McInnis N.H.
        • Fodor G.
        • Lum-Kwong M.M.
        • Leenan F.H.
        Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ON-BP).
        Am J Hypertens. 2008; 21: 1210-1215